|
CNBC'S MOST SHARED
- A Goldman Trading Scandal?
- Rich People With A Death Wish
- The Threat of Ballooning Pensions
- Lehman CEO: Firm Deserved Bailout or 'Wind Down'
- SEC May Reinstate Rules for Short-Selling Stocks
- Market's Monday Blues
- Is Andy’s Mojo Back? We Asked Him
- Your First Move For Monday July 6th
- China Launches Major Step to Yuan Internationalization
- Goldman Sees No Harm From Computer Programmer
- Farrell: Don't Head For The Exits Yet
- Justice Dept Said to Be Looking At Telecom Giants
- Lehman CEO: Firm Deserved Bailout or 'Wind Down'
- US Service Sector Has Best Showing In Months
- GM A Step Closer To Exiting Bankruptcy
- Tribune, Cubs Deal Agreed In Principle
- Facebook Director Sees 'Billions' in Revenue in 5 Years
- Judge Gives Control of Jackson Estate to Executors
- Hey, What's Up Doc?
- Busch: Summertime Blues Hits Investors
- Chadwick: Recession and Scandals Pave the Way for Romney 2012
- Art Cashin: The S&P's 'Head and Shoulders' Number
- Michael Jackson: Death And Taxes
- Is Andy’s Mojo Back? We Asked Him
- GM A Step Closer To Exiting Bankruptcy
- Schork Oil Outlook: The Fear Trade
- Market's Monday Blues
AstraZeneca Wins Bar on Generic Pulmicort
Text Size 
Anglo-Swedish drugmaker AstraZeneca said on Thursday it had been granted a temporary U.S. court order suspending sales of a generic version of its asthma drug Pulmicort by rival Teva.
 |
AP |
Under the ruling, AstraZeneca and partner Par Pharmaceuticals will also suspend sales of their generic version of Pulmicort.
The restraining order remains in force until further order of the court. A preliminary injunction hearing is scheduled for Nov. 25 with a full court case due to start on Jan. 12.
AstraZeneca warned on Wednesday its full-year earnings would be at the lower end of its previously stated range as a result of the launch of generic Pulmicort, hammering its shares.
© 2008 CNBC.com
Print
Email
MORE FROM CNBC
Data is a real-time snapshot *Data is delayed at least 15 minutes